| Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative … M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ... Circulation 136 (3), 249-259, 2017 | 793 | 2017 |
| Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study M Kosiborod, CSP Lam, S Kohsaka, DJ Kim, A Karasik, J Shaw, N Tangri, ... Journal of the American College of Cardiology 71 (23), 2628-2639, 2018 | 505 | 2018 |
| Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs … KI Birkeland, ME Jørgensen, B Carstensen, F Persson, HL Gulseth, ... The lancet Diabetes & endocrinology 5 (9), 709-717, 2017 | 398 | 2017 |
| Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review K Khunti, MB Gomes, S Pocock, MV Shestakova, S Pintat, P Fenici, ... Diabetes, Obesity and Metabolism 20 (2), 427-437, 2018 | 383 | 2018 |
| Part 8: advanced life support: 2010 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations LJ Morrison, CD Deakin, PT Morley, CW Callaway, RE Kerber, SL Kronick, ... Circulation 122 (16_suppl_2), S345-S421, 2010 | 380 | 2010 |
| Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study HJL Heerspink, A Karasik, M Thuresson, C Melzer-Cohen, G Chodick, ... The lancet Diabetes & endocrinology 8 (1), 27-35, 2020 | 321 | 2020 |
| Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program) M Kosiborod, MB Gomes, A Nicolucci, S Pocock, W Rathmann, ... Cardiovascular diabetology 17, 1-13, 2018 | 251 | 2018 |
| Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl … F Persson, T Nyström, ME Jørgensen, B Carstensen, HL Gulseth, ... Diabetes, Obesity and Metabolism 20 (2), 344-351, 2018 | 245 | 2018 |
| Part 5: adult basic life support: 2010 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations MR Sayre, RW Koster, M Botha, DM Cave, MT Cudnik, AJ Handley, ... Circulation 122 (16_suppl_2), S298-S324, 2010 | 238 | 2010 |
| CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering … M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ... Circulation 136 (3), 249-259, 2017 | 178 | 2017 |
| Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: an analysis of the NHANES surveys … H Caspard, S Jabbour, N Hammar, P Fenici, JJ Sheehan, M Kosiborod Diabetes, Obesity and Metabolism 20 (3), 667-671, 2018 | 159 | 2018 |
| SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL MA Cavender, A Norhammar, KI Birkeland, ME Jørgensen, JP Wilding, ... Journal of the American College of Cardiology 71 (22), 2497-2506, 2018 | 143 | 2018 |
| Lower risk of death with SGLT2 inhibitors in observational studies: real or bias? S Suissa Diabetes care 41 (1), 6-10, 2018 | 131 | 2018 |
| Treatment of type 2 diabetes mellitus worldwide: baseline patient characteristics in the global DISCOVER study MB Gomes, W Rathmann, B Charbonnel, K Khunti, M Kosiborod, ... Diabetes research and clinical practice 151, 20-32, 2019 | 125 | 2019 |
| Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ... Circulation 136 (3), 249-259, 2017 | 119 | 2017 |
| Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk F Giorgino, J Vora, P Fenici, A Solini Cardiovascular Diabetology 19, 1-19, 2020 | 90 | 2020 |
| Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study S Kohsaka, CSP Lam, DJ Kim, MA Cavender, A Norhammar, ... The Lancet Diabetes & Endocrinology 8 (7), 606-615, 2020 | 88 | 2020 |
| Rates of myocardial infarction and stroke in patients initiating treatment with SGLT 2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: R esults … M Kosiborod, KI Birkeland, MA Cavender, AZ Fu, JP Wilding, K Khunti, ... Diabetes, Obesity and Metabolism 20 (8), 1983-1987, 2018 | 82 | 2018 |
| Burden of cardio‐renal‐metabolic conditions in adults with type 2 diabetes within the diabetes collaborative registry SV Arnold, M Kosiborod, J Wang, P Fenici, G Gannedahl, RJ LoCasale Diabetes, Obesity and Metabolism 20 (8), 2000-2003, 2018 | 80 | 2018 |
| What is the optimal chest compression-ventilation ratio? P Fenici, AH Idris, KG Lurie, S Ursella, A Gabrielli Current opinion in critical care 11 (3), 204-211, 2005 | 75 | 2005 |
